| 11/1/2012 | CVLM | Human Genome sets 'increase period' for conversion of 3% notes
|
| 9/7/2012 | CVLM | Human Genome sets 'increase period' for conversion of 3% notes
|
| 8/3/2012 | CVLM | Human Genome announces dates for make-whole conversion period, put
|
| 8/1/2012 | CVLM | Human Genome announces put option, make-whole conversion adjustment
|
| 7/16/2012 | CV | Market Commentary: Human Genome mixed on takeout news; Alpha Natural down after stock downgrade; Regis adds
|
| 5/17/2012 | CV | Market Commentary: Dendreon declines after J&J drug news; Patriot Coal keeps sliding; Chesapeake lower again
|
| 5/9/2012 | CV | Market Commentary: Reoffered Annaly steady; Chiquita down after earnings; Human Genome unfazed by hostile bid
|
| 4/23/2012 | CV | Market Commentary: Central European Distribution jumps on investment; Amylin up; James River Coal plunges
|
| 4/20/2012 | CV | Market Commentary: SanDisk slides outright, adds on hedge; Chesapeake flat to lower; AMR adds on merger talk
|
| 4/19/2012 | CV | Market Commentary: Human Genome adds outright, slides on hedge; New Titan gains dollar neutral; Gilead mixed
|
| 4/4/2012 | CV | Market Commentary: SanDisk 1.5% convertibles come in on hedge; NetApp trades in line; Western Refining adds
|
| 2/7/2012 | CV | Market Commentary: Coinstar jumps after earnings, Verizon deal; Dendreon edges slightly higher after pop
|
| 1/25/2012 | CV | Market Commentary: Illumina 'rips' higher outright, expands on hedge; Life, Human Genome move in sympathy
|
| 1/12/2012 | CV | Market Commentary: Human Genome premium expands; new PHH extends gains; Petroplus, Sino-Forest in focus
|
| 12/30/2011 | CV | Outlook 2012: Convertibles primary market set for weakness without higher rates, stronger economy
|
| 11/15/2011 | CV | Market Commentary: Goldcorp active; Meritor, ViroPharma shed about a point on swap; Air Lease deal revised
|
| 11/14/2011 | CV | Market Commentary: Central European Distribution, Savient extend losses; Newer Human Genome premium rises
|
| 11/3/2011 | CV | Human Genome greenshoe exercise ups 3% convertibles to $494.5 million
|
| 11/3/2011 | CV | Market Commentary: Jefferies extends losses; New Human Genome paper flat dollar neutral; MGM adds premium
|
| 11/2/2011 | CV | New Issue: Human Genome sells upsized $430 million 3% seven-year convertibles at discount of 99
|
| 11/2/2011 | CV | Market Commentary: Human Genome's new $430 million deal prices at 99, edges higher; MF Global adds a little
|
| 11/2/2011 | CVLM | Human Genome may buy back 2.25% convertibles with new issue proceeds
|
| 10/24/2011 | CV | Market Commentary: Convertibles rise on light volume; Radian up; hedged players lose on RightNow's Oracle offer
|
| 10/21/2011 | CV | Market Commentary: SanDisk moves up on positive earnings; Old Nuance opens up; Investment-grade names active
|
| 10/5/2011 | CV | Market Commentary: Microsoft convertibles gain on reported Yahoo! bid; Hologic, Human Genome head upward
|
| 9/21/2011 | CV | Market Commentary: Medtronic wins patent case against NuVasive; Human Genome gains; Alpha pulls down coal
|
| 8/1/2011 | CVLM | Human Genome exchanges $77.53 million of 2.25% convertibles for stock
|
| 7/12/2011 | CV | Market Commentary: Convertibles fall; Europe fears build with Ireland's downgrade; volumes low amid volatility
|
| 11/11/2010 | CV | Market Commentary: Human Genome climbs on takeover hopes; DryShips takes off on stock upgrade; UAL higher
|
| 9/27/2010 | CV | Market Commentary: LDK paper jumps on new borrowing agreement; AirTran surges on merger deal; Newpark on tap
|
| 7/12/2010 | CV | Market Commentary: Transocean gains on Gulf progress; Human Genome, Microsoft up with market; Alcoa moves higher
|
| 7/9/2010 | CV | Market Commentary: Airline names higher; Xilinx, Sirius improve; Transocean strong; but Cheniere Energy falls
|
| 6/28/2010 | CV | Market Commentary: Convertibles mixed on light volume; Navistar better; ProLogis down in line; Cephalon adds
|
| 4/9/2010 | CV | Market Commentary: Convertibles action crimped by low vol., vacations; Cephalon, Human Genome gain; Ford off
|
| 3/2/2010 | CV | Market Commentary: Newmont falls; Human Genome up on earnings, health care names bid higher; Annaly sells add-on
|
| 1/11/2010 | BWCV | Human Genome expects to end 2009 with $1.2 billion cash, investments
|
| 1/8/2010 | CV | Market Commentary: Convertibles secondary active; Titan, DryShips richen; PetroBakken sells $750 million deal
|
| 12/1/2009 | CV | Market Commentary: Convertibles action revives; gold names in focus; Energy XXI, Sino-Forest launch new deals
|
| 11/2/2009 | CV | Market Commentary: YRC jumps on exchange; Vornado up on tender; Human Genome surges on lupus drug; Ford to price
|
| 10/29/2009 | CVHY | Human Genome files automatic shelf covering stock, debt, preferreds
|
| 10/19/2009 | CV | Market Commentary: Lincare flat to higher, Steel Dynamics steady; GMX Resources, Forest City, Dole to price
|
| 9/14/2009 | CV | Market Commentary: PDL BioPharma, Human Genome in trade amid takeout talk; Magma finalizes exchange offer
|
| 8/26/2009 | CV | Market Commentary: Textron, International Game add; Transocean slips; Charming Shoppes gains in quiet tradee
|
| 8/25/2009 | CV | Market Commentary: Human Genome strengthens on takeover talk; AMD extends gains; Radio Shack marketed at 99.75
|
| 8/4/2009 | CV | Market Commentary: Hologic higher on earnings, forecast; Vale, Human Genome gain after upgrades; Onyx plans deal
|
| 7/27/2009 | CV | Sell Human Genome 2012 convertibles, buy 2011 issue, Barclays advises
|
| 7/24/2009 | CV | Market Commentary: Intel eyed as volume name; Ingersoll-Rand, Actuant strong; Human Genome gains more; Medarex over par
|
| 7/23/2009 | CV | Market Commentary: Earnings help convertibles extend strength; Ford gains on profit; OSI, Human Genome higher
|
| 7/20/2009 | CV | Market Commentary: Human Genome surges on lupus trial; Lincare trades before earnings; CIT busy; Intel to price
|
| 7/16/2009 | CV | Market Commentary: CIT preferred gets crushed, mandatory steady; Janus jumps on debut; Human Genome mostly quiet
|
| 6/3/2009 | CV | Market Commentary: Convertibles quiet as players eye JetBlue, Biovail, Steel Dynamics; Cephalon, Human Genome up
|
| 2/26/2009 | CV | Human Genome Sciences buys back $106.2 million of its 2.25% convertibles due 2011, 2012
|
| 2/6/2009 | CV | Market Commentary: Convertibles strengthen: shorter-dated paper adds 0.375 to 0.5 point; B of A surges; AMD gains
|
| 1/30/2009 | CV | Market Commentary: Alliant Techsystems active, little changed; financials ease amid uncertainty; Newmont extends gains
|
| 12/5/2008 | CV | Market Commentary: Nabors little changed on lower oil; GM, Ford mixed; Sinclair Broadcast for sale, but no buyers seen
|
| 12/1/2008 | CVHY | Human Genome Sciences files $400 million shelf registration
|
| 1/23/2008 | CV | Market Commentary: National City, Kinross Gold set to price, looking cheap; BofA bringing billions; Human Genome slashed
|
| 6/11/2007 | CV | Market Commentary: MannKind takes off; Molson quiet in gray; Human Genome rebounds; three REITs, Trex launch deals
|
| 10/5/2006 | CV | Market Commentary: Forest City gains modestly on debut; HRPT upsizes deal; United Dominion prices; Human Genome climbs
|
| 9/18/2006 | CV | Market Commentary: XM Satellite maintains climb; Commonwealth climbs on takeover; Human Genome keeps tightening
|
| 5/1/2006 | CV | Market Commentary: Level 3 gains on $1.2 billion acquisition; Teva gets court boost; Human Genome tightens on drug trials
|
| 3/15/2006 | CV | Market Commentary: Waste Connections gains on debut; Universal ups premium in talk; CSX, PMC-Sierra gain on upgrades
|
| 3/14/2006 | CV | Market Commentary: Fair Isaac plunges on fears of new rival product; Human Genome slides on mixed trial results
|
| 2/16/2006 | CV | Market Commentary: Amgen convertibles active in trade; Halliburton gains; XM Satellite lower
|
| 1/19/2006 | CV | Market Commentary: Advanced Micro, Cypress gain, but Intel weaker; Hutchinson prices upsized $225 million deal
|
| 1/9/2006 | CV | Market Commentary: Convertibles market extends gains; Human Genome, GM, Delta Air Lines, Duke up
|
| 11/9/2005 | CV | Market Commentary: Convertibles still weak, Blockbuster lower; but new issues heat up with $2 billion Prudential deal
|
| 11/8/2005 | CV | Human Genome Sciences to redeem 33/4%, 5% convertible notes due 2007
|
| 11/4/2005 | CV | Market Commentary: Qwest, Chesapeake remain active; Celgene up, Emdeon lower; King sideways
|
| 11/1/2005 | CV | Market Commentary: Qwest, Chesapeake Energy to price $2 billion-plus in convertibles; new IPC paper trades actively
|
| 10/25/2005 | BTCV | Human Genome buys back $177.5 million in convertible notes
|
| 10/5/2005 | CV | Market Commentary: Human Genome, ADC drop outright; Mercury Interactive steady, shares lower; Freeport-McMoRan down
|
| 9/19/2005 | CV | Market Commentary: CapitalSource jumps; GM, Ford, retail names weaken; two new deals launched
|
| 9/6/2005 | CV | Market Commentary: Chiron trades mixed, but Curagen gains; Dobson Communications to price $150 million issue
|
| 8/12/2005 | CV | Market Commentary: JDS Uniphase, Human Genome weaken in thinly traded convertibles market
|
| 8/5/2005 | CV | Market Commentary: LifePoint closes higher; Human Genome also gains, but automaker, REIT convertibles track lower
|
| 8/4/2005 | CV | Market Commentary: Affordable Residential issue rises; Human Genome loses ground; LifePoint prices after the close
|
| 8/4/2005 | BTCV | New Issue: Human Genome prices $230 million seven-year convertibles to yield 2.25%, up 20%
|
| 8/3/2005 | CV | Market Commentary: Human Genome to price $230 million of convertibles; Reebok paper jumps on buyout news
|
| 8/3/2005 | CV | Human Genome to buy back 5%, 33/4% convertibles with new deal proceeds
|
| 8/3/2005 | BTCV | Human Genome to price $230 million of seven-year convertibles to yield 2.25%, up 20%
|
| 7/26/2005 | CV | Market Commentary: GM up on GMAC financing; Ford, DaimlerChrysler mixed; Manor Care, Barnes at bat; Fairmont Hotels falls
|
| 7/11/2005 | CV | Market Commentary: Northwest Airlines spurs airlines convertibles; Schlumberger extends gains; but biotech, technology ease
|
| 3/21/2005 | CV | Human Genome files $400 million shelf
|
| 12/7/2004 | CV | Market Commentary: CMS new deal bid at issue; Dress Barn bid up 3.5 points; Seacor launches overnighter
|
| 10/19/2004 | CV | Human Genome Sciences buys back $218.1 million 33/4% convertibles, $60.1 million 5% convertibles
|
| 10/4/2004 | CV | Human Genome greenshoe partially exercised, raising convertibles to $280 million
|
| 9/30/2004 | CV | S&P rates Human Genome convertible CCC
|
| 9/29/2004 | CV | New Issue: Human Genome upsized $250 million convertible at 2.25%, up 40%
|
| 9/29/2004 | CV | Market Commentary: Human Genome straddles par; Calpine's issue falls 3 points; Charter off; United Rentals up
|
| 9/28/2004 | CV | Human Genome $200 million convertible talk amended to 2.25% yield, premium richened to 40% from 30%-35%
|
| 9/28/2004 | CV | Market Commentary: Human Genome up 1.5 in gray on tighter talk; Calpine, American Financial issues up; Lions Gate emerges
|
| 9/27/2004 | CV | Human Genome $200 million convertible talked at 2.25%-2.75% yield, up 30%-35%
|
| 9/27/2004 | CV | Market Commentary: Human Genome, American Financial deals emerge; new Calpine issue quiet; AtheroGenics soars after-hours
|
| 9/27/2004 | CV | Human Genome Sciences to buy back convertibles with $200 million offering proceeds
|
| 3/26/2004 | CV | S&P: Human Genome unaffected
|
| 1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
| 7/12/2002 | CV | Market Commentary: Market holds firm against dip in stocks as more buyers emerge
|
| 6/27/2002 | CV | Market Commentary: Market volatility creates trading opportunities; selling continues in telecom, spreads to media
|
| 4/10/2002 | CV | JPMorgan recommends 9 biotech convertibles for yield, capital appreciation, relative value
|
